Mussa H Almalki
Overview
Explore the profile of Mussa H Almalki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
H Almalki M, A Alsuraikh M, Almalki E, Aziz F, Almazrouei R, M AlDahmani K, et al.
Pituitary
. 2024 Mar;
27(2):238.
PMID: 38478212
No abstract available.
2.
H Almalki M, A Alsuraikh M, Almalki E, Aziz F, Almazrouei R, M AlDahmani K, et al.
Pituitary
. 2024 Feb;
27(2):197-203.
PMID: 38345719
Background: Impulse control disorders (ICDs) have been described as underrecognized side effects of dopamine agonists (DAs) in neurological disorders but are not sufficiently understood in endocrine conditions. Objective: To identify...
3.
Assessment of calcium intake and recognition of calcium-rich food sources among the Saudi population
Alshahrani F, Alassafi M, Owaiwid L, Alageel N, Alanazi F, Alsogami L, et al.
Arch Osteoporos
. 2023 Oct;
18(1):130.
PMID: 37884818
Introduction: Calcium is an essential mineral and one of the most prevalent in the body. Chronic insufficient calcium intake increases the risk of osteopenia, osteoporosis, and bone fracture. Purpose: This...
4.
H Almalki M, Aldesokey H, Alkhafaji D, Alsheikh A, Braae U, Lehrskov L, et al.
Adv Ther
. 2022 Nov;
40(2):568-584.
PMID: 36417058
Introduction: Insulin degludec (degludec) has proven benefits in type 2 diabetes (T2D), in terms of improved glycaemic control, low risk of hypoglycaemia, and flexibility in dosing time. This prospective non-interventional...
5.
Al Dahmani K, H Almalki M, Ekhzaimy A, Aziz F, Bashier A, Mahzari M, et al.
Pituitary
. 2022 Jul;
25(4):658-666.
PMID: 35793046
Introduction: Hypogonadism is the most common form of hypopituitarism in men with macroprolactinoma. However, evidence on factors related to hypogonadism recovery is limited. Objectives: We estimated the proportion of hypogonadism...
6.
Fallatah W, Brema I, Alobedallah A, Alkhathami R, Zaheer S, Almalki E, et al.
Avicenna J Med
. 2022 May;
12(1):10-15.
PMID: 35586391
Adjunctive treatment with sodium-glucose co-transporters 2 inhibitors (SGLT2- I) has been successfully used in patients with type 1 diabetes mellitus (T1DM) in recent years to improve glycemic control and reduce...
7.
H Almalki M, Ahmad M, Brema I, AlMehthel M, M AlDahmani K, Mahzari M, et al.
Sultan Qaboos Univ Med J
. 2021 Sep;
21(3):354-364.
PMID: 34522399
Central diabetes insipidus (CDI) is a common complication after pituitary surgery. However, it is most frequently transient. It is defined by the excretion of an abnormally large volume of dilute...
8.
Allehaibi E, H Almalki M, Brema I
J Med Case Rep
. 2021 Jul;
15(1):407.
PMID: 34321093
Background: Plurihormonal pituitary adenomas are a unique type of pituitary adenomas that secrete two or more pituitary hormones normally associated with separate cell types that have different immunocytochemical and ultrastructural...
9.
Alzahrani B, Alzahrani S, H Almalki M, Elabd S, Khan S, Buhary B, et al.
Clin Med Insights Endocrinol Diabetes
. 2021 May;
14:11795514211013789.
PMID: 34017209
Background: Glucose variability (GV) is a common and challenging clinical entity in the management of people with type 1 diabetes (T1DM). The magnitude of GV in Saudi people with T1DM...
10.
Al Mohareb O, Al Saqaaby M, Ekhzaimy A, Hamza M, H Almalki M, Bamehriz F, et al.
Clin Med Insights Endocrinol Diabetes
. 2021 Feb;
14:1179551420988523.
PMID: 33613038
Background/objectives: Thyroid function tests (TFTs) changes in obese people have been studied with increasing interest, however, studies have been inconsistent hence it remains poorly understood. We compared the TFTs of...